The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials / Dowsett, M; Forbes, J. F; Bradley, R; Ingle, J; Aihara, T; Bliss, J; Boccardo, F; Coates, A; Coombes, R. C; Cuzick, J; Dubsky, P; Gnant, M; Kaufmann, M; Kilburn, L; Perrone, F; Rea, D; Thürlimann, B; van de Velde, C; Pan, H; Peto, R; Davies, C; Gray, R; DE LAURENTIIS, Michelino. - In: THE LANCET. - ISSN 0140-6736. - 386:10001(2015), p. 1341-52. [10.1016/S0140-6736(15)61074-1]
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
DE LAURENTIIS, MICHELINO
2015
Abstract
The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS0140673615610741.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
638.57 kB
Formato
Adobe PDF
|
638.57 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
